(CercleFinance.com) – UCB shares outperformed on the Brussels Stock Exchange on Friday following the publication of positive results on bimekizumab in the treatment of psoriatic arthritis.
The title is currently limiting its decline to 0.1%, while the BEL 20 index is losing 1.8%.
The Belgian biopharmaceutical company reported on Friday the success of a Phase 3 study of bimekizumab, which met its primary endpoint of achieving at least a 50% improvement in the signs and symptoms of the disease compared to a placebo.
The study was carried out with 400 patients followed for at least six months, on whom TNF alpha inhibitors, an existing treatment, did not work.
Based on these results, UCB expects to file marketing authorization applications with the US and European authorities during the third quarter.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
